These reports indicate the potential role of the miR-200 family-CAGE-EGFR-PD-L1 molecular network in the resistance to immune checkpoint inhibitors, EGFR-tyrosine kinase inhibitors (EGFR-TKIs), and other anti-cancer drugs. The gene discussed is EGFR; the disease is cancer.